IndieBio

IndieBio, established in 2014, is a San Francisco-based accelerator firm specializing in Synthetic Biology. It runs intensive four-month programs for early-stage companies and teams with innovative biological concepts. IndieBio invests in seed and early-stage startups globally, focusing on those that use biology as their core technology to solve real-world problems. The firm typically invests $250k, with an initial cash investment of $50k in exchange for an 8% equity stake. It prefers teams with at least two co-founders. IndieBio was the world's first accelerator dedicated to biology-based startups, aiming to address global challenges through innovative biotechnology.

Arvind Gupta

Founder

Parikshit Sharma

Partner

Past deals in Biotechnology

Fermeate

Seed Round in 2025
Fermeate is a stealth-mode biotechnology company that specializes in photomolecular fermentation technology. This innovative approach aims to enhance sustainability and efficiency within the biomanufacturing industry.

Materia Bioworks

Seed Round in 2025
Materia Bioworks is a pioneering company that develops data-driven informatics tools to facilitate the creation and adoption of sustainable biomaterials. Their AI-powered platform streamlines the process of developing and manufacturing biomaterial products, from sourcing materials to final production. This enables material scientists, product developers, suppliers, and converters to accelerate and enhance their work in biomaterial applications, fostering a more sustainable future across various industries.

Prellis Biologics

Series C in 2025
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

PunaBio

Series A in 2025
PunaBio is a Buenos Aires-based company that develops biological products aimed at enhancing agricultural productivity through environmentally friendly methods. By utilizing extremophile microorganisms, PunaBio focuses on improving crop nutrition, which contributes to increased yields and better crop quality. Their products are designed to enable farmers to cultivate crops on degraded soils and restore and enrich agricultural land sustainably. This approach not only helps improve farmers' productivity but also promotes sustainable agricultural practices.

Particella

Convertible Note in 2025
Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

Giraffe Bio

Seed Round in 2024
Giraffe Bio specializes in developing biomolecular technology to enhance the efficiency and sustainability of critical mineral extraction. Their platform tailors biomolecules to the specific geology of each mine, boosting metal recovery, reducing water consumption, and minimizing environmental impact. This is achieved by integrating biology, artificial intelligence, and hardware to optimize extraction processes.

Ten63 Therapeutics

Series A in 2024
Ten63 Therapeutics is a biotechnology company focused on developing innovative therapeutics for challenging diseases, particularly those involving targets previously considered undruggable. Founded in 2017 and based in Chapel Hill, North Carolina, the company utilizes its proprietary platform, COPPER, which integrates advanced artificial intelligence and state-of-the-art physical models to explore vast chemical spaces. By employing low-residual, machine learning-based computational chemistry alongside superlinear search algorithms, Ten63 Therapeutics aims to identify and optimize drug candidates effectively. Their approach includes proprietary scaffold redesign and hopping technology, enabling the screening of trillions of molecules to predict resistance and redesign antibodies. This combination of techniques positions Ten63 Therapeutics at the forefront of developing durable treatments for some of the most lethal diseases.

AlkaLi Labs

Convertible Note in 2024
AlkaLi Labs is a biotechnology research company based in San Francisco, California, established in 2023. The company focuses on developing biological solutions to harness domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology, leveraging biological processes to unlock valuable minerals.

Unlocked Labs

Seed Round in 2024
Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

BioLattice

Seed Round in 2024
BioLattice is a biotechnology company focused on developing tissue-engineered cornea technology. Their primary goal is to provide a viable alternative to donor tissue for full-thickness corneal transplants. The company's innovative technology offers a corneal prototype with vision-correcting capabilities, aiming to restore sight for patients requiring corneal transplants.

ViAn Therapeutics

Seed Round in 2024
VIAN Therapeutics is an early-stage biotechnology company dedicated to innovating treatments for retinal diseases. The company is developing a first-in-class, non-invasive eyedrop intended to replace traditional injections for conditions such as age-related macular degeneration and diabetic macular edema. With robust preclinical data and ongoing clinical trials, VIAN aims to meet significant unmet medical needs in the retinal disease market, which is valued at $15 billion. Additionally, the company is engaged in the creation of peptide drugs that enhance efficacy and safety for treating both ophthalmic and oncology-related conditions by targeting angiogenesis, thereby offering patients improved health outcomes.

Asterix Foods

Convertible Note in 2024
Asterix Foods is a biotechnology company based in Tel Aviv, Israel, founded in 2022. The company specializes in developing protein production using plant-cell culture techniques. Its platform focuses on creating bioactive proteins for food that are scalable, functional, and complex. Asterix Foods aims to provide users with plant cell-cultured and animal-free proteins, contributing to innovative and sustainable food solutions.

Sci-Lume Labs

Seed Round in 2024
Sci-Lume Labs specializes in the development of innovative, bio-based and biodegradable fibers designed to replace conventional petrochemical fibers like nylon and polyester. Their high-performance materials maintain the functionality and versatility of traditional synthetics while addressing environmental concerns, catering to textile and apparel manufacturers seeking sustainable alternatives.

Quorum Earth

Seed Round in 2024
Quorum Earth, based in Brooklyn, New York, is a pioneering agricultural technology company. It specializes in the development of innovative, eco-friendly pesticides, harnessing the power of the fungal kingdom to create products that are safe for the planet and effective in controlling pests. Currently, the company operates in stealth mode.

Capra Biosciences

Convertible Note in 2024
Capra Biosciences is a biotechnology company focused on the efficient and low-carbon production of everyday chemicals through innovative bioreactor technology. The company has developed a biofilm bioreactor platform that aims to enhance the bio-manufacturing process by significantly reducing downstream processing requirements and associated costs. This technology facilitates the production of a variety of bio-based chemicals, including hydrophobic products like retinol and performance lubricants, thus advancing sustainable practices in the chemical industry.

Synplexity

Seed Round in 2024
Synplexity, based in New Castle, Delaware, specializes in biotechnology. It offers mutational scanning and multiplexed gene synthesis services, leveraging artificial intelligence. The company's platform, utilizing microdroplets as microreactors, enables the creation of multiplex gene libraries, benefiting various sectors such as therapeutics, biomanufacturing, agriculture, and climate systems.

Laguna Bio

Seed Round in 2024
Laguna Bio is a biotechnology company based in Berkeley, California, founded in 2022. The company focuses on drug discovery, specifically developing a platform that activates and expands the innate immune system to combat cancer. Laguna Bio specializes in enhancing a specific type of T cell that targets solid tumors, aiming to improve the efficacy of bispecific antibody drugs. By increasing the immune response against these tumors, the company seeks to provide innovative solutions that may help patients survive cancer more effectively.

FREZENT

Seed Round in 2024
FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

NanoPlume

Seed Round in 2024
NanoPlume is a biomaterial company specializing in the large-scale production of innovative biomaterials, notably Bio-Aerogel. It manufactures advanced insulating biomaterials and aerogels, designed to enhance energy and space efficiency, and promote circularity across various industries. The company employs organic and recycled feedstocks, along with green technology, to minimize waste and reduce energy consumption. Its products aim to improve cold chain logistics by insulating cargo boxes, reducing payload and energy consumption, and extending battery range.

Huue

Convertible Note in 2024
Huue is a company focused on providing sustainable dyeing solutions for the denim and textile industries, specifically through the use of bio-synthesized indigo dyes. By employing fermentation biotechnology, the company utilizes naturally occurring microorganisms to produce colors, which significantly reduces the reliance on toxic chemicals traditionally used in dye production. This innovative approach not only enhances the environmental sustainability of the denim supply chain but also offers a greener alternative for fashion and textile manufacturers seeking to create eco-friendly products. Huue's commitment to harnessing renewable resources positions it as a leader in the movement towards more sustainable practices in the industry.

DisperseBio

Seed Round in 2024
DisperseBio is a Biotechnology Research firm developing a mechanism to counter microbial contamination on natural surfaces like human body.

Minutia

Seed Round in 2024
Minutia is focused on developing innovative solutions for Type 1 Diabetes through stem cell-derived transplants that incorporate nanosensors. The company specializes in creating subcutaneous insulin-producing cell transplants that are immune-evasive and capable of real-time monitoring via proprietary cell-based sensors. This approach aims to address common challenges associated with transplants and seeks to provide a functional cure for diabetes. By advancing both transplantation techniques and monitoring capabilities, Minutia aspires to transform the clinical landscape of diabetes management and cell replacement therapies.

Sóliome

Seed Round in 2024
Sóliome is a biotechnology company founded in 2021 and based in San Francisco, California. The company specializes in developing protein-based sunscreens designed to be safe for both the skin and the environment. These innovative products aim to reduce inflammation and skin damage caused by traditional sunscreens, which often contain harmful xenobiotic ingredients that can absorb into the skin and contribute to ecological harm. Sóliome's approach allows customers to protect their skin from harmful rays without the adverse effects associated with conventional sunscreen formulations.

Gatehouse Bio

Convertible Note in 2024
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Calyx

Funding Round in 2024
Calyx develops advanced sensor platforms that monitor various parameters in poultry and livestock, utilizing cutting-edge technology to address complex challenges in the industry. The company specializes in gas sensor technology that detects airborne chemical emissions through innovative sensors patterned with viruses that bind to specific gas molecules. These sensors provide high specificity and sensitivity, changing color in response to different gases and their concentrations. By integrating artificial intelligence, computer vision technology, and data science, Calyx aims to enhance environmental monitoring and improve health outcomes for livestock and poultry, offering commercial customers effective solutions to track daily environmental changes.

BioMetallum

Seed Round in 2024
BioMetallum is a biomining company specializing in sustainable metal extraction. It designs and develops solutions, primarily focused on lithium, using microorganisms to enhance efficiency and minimize environmental impact. The company's services promote a circular economy, aiming to enable a healthier, more sustainable society.

Asta Bio

Seed Round in 2024
Asta Bio is a biotechnology company specializing in the development of radiotherapeutics for cancer treatment. It focuses on combining the alpha-emitting radioisotope 211-Astatine with multivalent single-domain antibodies to deliver targeted alpha radiation to tumor cells, sparing healthy cells. This approach aims to effectively destroy cancer cells by breaking their DNA strands.

DNAzyme

Pre Seed Round in 2024
DNAzyme is a biotechnology company specializing in the development of enzymes derived from Antarctic extremophile microorganisms as active ingredients for skin health applications. Utilizing recombinant DNA repair technology, the company produces highly pure enzymes at an industrial scale, enabling clinicians to create innovative solutions for skin health and rejuvenation in both the cosmetic and pharmaceutical industries.

Tinkeso Therapeutics

Seed Round in 2024
Tinkeso Therapeutics is a biotechnology company specializing in the development of innovative cell therapies for treating cancer and autoimmune diseases. The company focuses on creating off-the-shelf, allogeneic chimeric antigen receptor (CAR) engineered natural killer T (NKT) cell therapies. These therapies use NKT cells to target and destroy cancer cells or modulate the immune response in autoimmune conditions, aiming to increase treatment accessibility and scalability.

heXem bio

Seed Round in 2024
heXem bio specializes in recording solutions for the early development of humans for longevity.

Bugbiome

Seed Round in 2024
BugBiome is a biotechnology company that develops eco-friendly bio-repellents to create natural pest control products. It focuses on identifying and enhancing beneficial microbes that deter pests organically, providing an alternative to traditional chemical methods. The company aims to minimize environmental impact and promote sustainable pest management practices, potentially benefiting sectors such as agriculture and households.

Semion

Convertible Note in 2024
Restoring crops' ability to defend against pests.

Fermeate

Seed Round in 2024
Fermeate is a stealth-mode biotechnology company that specializes in photomolecular fermentation technology. This innovative approach aims to enhance sustainability and efficiency within the biomanufacturing industry.

Oobli

Series C in 2024
Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

CellCrine

Seed Round in 2024
CellCrine focuses on discovering enzymes that transform cell culture for the cell-based meats industry. CellCrine was founded in 2021and was headquartered in United, States.

MycoWorks

Series D in 2024
MycoWorks is a biotechnology company focused on developing sustainable, non-plastic and non-animal materials. Utilizing fungal mycelium, the company creates biodegradable alternatives to plastic foams, synthetic textiles, engineered woods, and leather. Their innovative products are designed for various applications, including aerospace, automobiles, apparel, and architectural interiors. By leveraging agricultural byproducts in a carbon-negative process, MycoWorks enables clients to access new types of leather that are grown rapidly and sustainably. This approach not only addresses environmental concerns but also offers practical solutions for industries seeking eco-friendly materials.

OncoPrecision

Convertible Note in 2024
OncoPrecision is a company that focuses on improving cancer therapy outcomes by utilizing a patient micro avatar platform. This innovative platform employs single-cell high-throughput biology and machine learning to generate comprehensive patient-derived phenotypic biomarkers. By doing so, it enables oncologists to make informed, data-driven decisions regarding the selection of cancer therapies tailored to individual patients. The approach aims to increase the success rates of cancer treatments by ensuring that the right therapy is matched to the right patient, thus enhancing overall patient care and treatment effectiveness.

Bugbiome

Seed Round in 2024
BugBiome is a biotechnology company that develops eco-friendly bio-repellents to create natural pest control products. It focuses on identifying and enhancing beneficial microbes that deter pests organically, providing an alternative to traditional chemical methods. The company aims to minimize environmental impact and promote sustainable pest management practices, potentially benefiting sectors such as agriculture and households.

Avalo

Series A in 2024
Avalo is a plant biology company that employs interpretable machine learning, genomic discovery, and evolutionary theory to innovate crop development for future agricultural needs. Utilizing AI-assisted plant breeding, Avalo ensures that all its products are non-GMO and promote natural biodiversity. The company's core technology is a discovery engine that efficiently identifies the genetic foundations of complex traits, significantly shortening the time and reducing the costs associated with developing new crops. By focusing on traits such as drought tolerance, water-use efficiency, and nutrient density, Avalo's platform enhances crop evolution to adapt to changing climate conditions. This approach allows researchers to improve crop quality while providing diagnostic forecasting and gene discovery capabilities, ultimately advancing agricultural practices.

HelEx

Convertible Note in 2024
Helex, founded in 2021 and based in New York, specializes in developing innovative genomic medicines specifically for renal conditions. The company leverages its proprietary genomics data and bioinformatics platform to create, verify, and distribute therapy-specific guide RNAs (gRNAs). By employing data-driven deep-learning models and high throughput next-generation sequencing data from CRISPR edits on human cell lines, Helex provides reliable predictions and validations in-house. This approach supports clients in expediting the development of CRISPR-based drug discovery and cell and gene therapies, emphasizing non-viral targeted delivery and genome editing for kidney-related therapies.

Calder Biosciences

Seed Round in 2024
Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

ClimateCrop

Seed Round in 2024
ClimateCrop is an agriculture technology company founded in 2021 and based in Ness Ziona. The company specializes in gene editing to enhance the ability of plants to store carbon and energy, thereby increasing crop yields in biomass and fruit production. By improving the resilience of crops to extreme weather conditions, ClimateCrop enables agricultural companies to better adapt to current and future climate challenges, ultimately leading to more sustainable and productive farming practices.

Finless Foods

Convertible Note in 2024
Finless Foods Inc. is a biotechnology company based in Emeryville, California, that specializes in producing seafood products for human consumption using cellular-agriculture technologies. Founded in 2017, the company focuses on growing marine-animal cells to create alternatives to traditional fish and seafood, including bluefin tuna. By offering a variety of responsibly produced food options, Finless Foods aims to cater to diverse tastes and dietary needs while promoting sustainability and better ocean health. The company's innovative approach provides consumers with healthy and accessible seafood alternatives, enabling them to maintain a balanced diet without compromising on flavor or variety.

Bloomlabs

Convertible Note in 2024
Bloomlabs provides a method to catalyze waste value by regenerating it as adaptable and appealing bio-plastics and textile fibers. It envisions a future in which outmoded, resource-intensive processes are phased out in favor of cutting-edge, sustainable, and scalable alternatives.

Cayuga Biotech

Convertible Note in 2024
Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

California Cultured

Series A in 2024
California Cultured is a food company based in Davis, California, that specializes in producing sustainable, lab-grown cocoa through advanced cellular agriculture techniques. Founded in 2020, the company aims to create cocoa that is less bitter and requires less sugar, enhancing the taste while promoting health benefits. By stimulating cocoa cells with common food ingredients, California Cultured ensures the growth of premium-quality cocoa without the ethical and environmental issues associated with traditional cocoa production, such as slavery and deforestation. This innovative approach allows customers to enjoy delicious cocoa products that are both sustainable and socially responsible.

Avisa Myko

Convertible Note in 2024
Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Reactosome

Seed Round in 2024
Reactosome is a biotechnology company that develops synthetic nuclei for gene therapy. Its core product, a synthetic nucleus, operates continuously within cells, mimicking the natural nucleus to affect multiple genes simultaneously. This approach aims to enhance the safety and longevity of gene expression, thereby enabling the healthcare industry to treat complex diseases such as cancers and age-related disorders more effectively.

Bioeutectics

Seed Round in 2024
Bioeutectics focuses on creating environmentally friendly industrial products by providing high-performance, natural solvents. Utilizing proprietary eutectic technology, the company produces solvents that mimic the natural processes of plants, using 100% renewable resources. This innovation allows Bioeutectics to replace traditional petrochemical solvents in various industrial applications, promoting sustainability. Their product line caters to diverse sectors, including food, pharmaceuticals, and personal care, and is designed to be non-toxic, biodegradable, and customizable to meet specific industry needs. Through these advancements, Bioeutectics aims to lead the market in offering sustainable alternatives that enhance environmental responsibility in industrial processes.

Zymochem

Series A in 2024
ZymoChem, Inc. is a biotechnology company based in Emeryville, California, founded in 2013. It specializes in the development of eco-friendly chemicals and bioprocesses using engineered microbes to convert renewable feedstocks, such as sugars, into industrial chemicals. The company’s bio-manufacturing platform aims to produce bio-based materials while minimizing carbon emissions during production, thereby supporting a carbon-efficient economy. By establishing cost-effective bioprocesses and novel biosynthetic pathways, ZymoChem enables clients to reduce production costs and enhance their competitiveness in the market. Through its innovative approach, the company contributes to sustainable manufacturing practices and the advancement of a real-zero economy.

Chronus Health

Convertible Note in 2024
Chronus Health, Inc. is a company that specializes in developing a portable diagnostic platform aimed at delivering rapid point-of-care lab results, specifically for complete blood count and comprehensive metabolic panel tests. Founded in 2017 and based in Mountain View, California, the company's innovative system utilizes microfluidics and semiconductor technology, combined with data analytics, to provide healthcare providers with real-time test results. This capability allows for immediate diagnosis at the point of care, enhancing the efficiency of treatment and significantly improving patient outcomes. By enabling doctors to obtain lab results in minutes, Chronus Health facilitates timely decision-making in clinical settings.

Unlocked Labs

Seed Round in 2023
Unlocked Labs specializes in developing innovative probiotics aimed at addressing chronic health conditions by utilizing genetically optimized microbial strains. The company focuses on activating dormant microbial abilities to effectively digest compounds that can lead to health issues. Their first product targets the risk of kidney stones by breaking down stone-forming compounds derived from healthy foods like leafy vegetables. Unlocked Labs employs alternative regulatory pathways to expedite the availability of safe and effective probiotic solutions for consumers. By harnessing the natural detoxifying capabilities of symbiotic microbes, their products aim to reduce acid levels in the body, making them both affordable and accessible to a wide audience.

RyboDyn

Seed Round in 2023
RyboDyn is a biotechnology research company focused on developing innovative therapeutics aimed at training the immune system to detect and eliminate cancer from within the body. The company is dedicated to advancing scientific breakthroughs that lead to new classes of treatments, providing significant improvements in medicine. RyboDyn's work is particularly concentrated on creating upgraded therapies for serious diseases, including terminal conditions, with the goal of enhancing patient outcomes and expanding treatment options.

Prellis Biologics

Series C in 2023
Prellis Biologics, Inc. specializes in creating human tissues for drug development and the eventual production of human organs for transplantation. Founded in 2016 and based in San Francisco, California, the company employs advanced bioprinting technology to develop vascularized human tissues and organs, aiming to overcome the challenges associated with microvasculature. Its innovative products include TissueWorkshop, Organoids, Vascular Bundles, Tissue Chips, and Holograph X. Prellis Biologics also focuses on accurately replicating the human immune response through lymph node organoids, which can be utilized for various applications such as antibody discovery and immunogenicity assessment. By addressing critical issues in early-stage drug development and translational pharmacology, Prellis Biologics seeks to improve patient outcomes in healthcare.

Hypercell Technologies

Seed Round in 2023
Hypercell Technologies focuses on developing innovative diagnostic tools and monoclonal antibodies aimed at controlling infectious diseases in animals. The company employs molecular biology techniques to create accurate in-farm diagnostic tools that deliver results in under one hour. This rapid testing capability, combined with their antibodies, allows veterinarians to effectively manage and mitigate the spread of viruses within production animal populations. Hypercell Technologies is committed to preventing potential pandemics in humans by addressing the root causes of infectious diseases in animal reservoirs.

Lillianah Technologies

Seed Round in 2023
Lillianah is a team of scientists dedicated to addressing environmental challenges through innovative carbon capture technology. Their focus is on optimizing the biological pump in oceans to restore balance to marine ecosystems adversely affected by pollution, fertilizer runoff, and various external factors. By harnessing the potential of oceans, Lillianah aims to reverse the negative impacts on the environment, contributing to a healthier planet.

Biofluff

Seed Round in 2023
BioFluff specializes in the production of plant-based fur aimed at replacing traditional animal and plastic furs in the fashion industry. Utilizing a patented process along with retrofitted equipment for faux-fur manufacturing, the company is establishing a scalable production model for its sustainable materials. BioFluff's products are made from organic renewable fiber plants and are developed without gene splicing, gene editing, or the use of petrochemicals and unsustainable raw-oil derivatives. Additionally, the company offers customization services, allowing customers to personalize various aspects of their products, including fur length, fiber density, color, and insulation properties. This commitment to sustainability positions BioFluff as a leader in providing luxury materials that align with eco-friendly practices.

Pyrone Systems

Seed Round in 2023
Pyrone Systems is a company focused on developing biopesticides that integrate biological and chemical principles to create safe and effective products. Founded in 2021, the company employs scalable methodologies to produce bio-based solutions that aim to replace harmful petrochemicals. By prioritizing sustainability, Pyrone Systems seeks to offer environmentally friendly alternatives in the agrochemical industry, thereby contributing to a reduction in the use of hazardous substances.

FREZENT

Seed Round in 2023
FREZENT is a biotechnology company focused on developing innovative therapeutics for advanced-stage cancer patients. It specializes in creating biological inhibitors that target cancer-specific lipid metabolism, aiming to prevent the reactivation of dormant cancer cells.

BioAesthetics

Convertible Note in 2023
BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

Gatehouse Bio

Convertible Note in 2023
Gatehouse Bio is a biotechnology company based in Waltham, Massachusetts, focused on the accelerated development of therapies utilizing small ribonucleic acid (RNA) and advanced bioinformatics. Founded in 2016, the company has developed a platform that employs artificial intelligence to identify error-free RNA biomarkers and discover disease-associated mutations. This platform enables precise classification of patient samples, which aids in the design of targeted therapeutics aimed at addressing various diseases, particularly in areas characterized by known heterogeneity such as fibrosis, inflammation, and neurodegeneration. By analyzing small RNA genes, Gatehouse Bio aims to unlock the potential for innovative treatments that could significantly enhance patient outcomes.

Diptera.ai

Convertible Note in 2023
Diptera.ai, based in Jerusalem, Israel, specializes in innovative mosquito control solutions. The company focuses on a biological method that utilizes sterile insect techniques, specifically by releasing sterile male mosquitoes through a ready-to-use module over a period of weeks. This technology incorporates advanced optics, computer vision, and artificial intelligence, making it both affordable and accessible for municipal corporations. By eliminating the need for mosquito rearing and sorting facilities, Diptera.ai enables large-scale mosquito control efforts, addressing public health concerns efficiently.

Calder Biosciences

Seed Round in 2023
Calder Biosciences is focused on developing next-generation vaccines to address significant public health challenges posed by evolving viruses. Their innovative 3D-Vaxlock technology enhances vaccine stability and efficacy by creating molecular structures that maintain the most effective shapes of immunogens. This approach aims to improve protection against respiratory syncytial virus (RSV), particularly for the elderly, and to create a universal flu vaccine effective against all seasonal strains. By addressing the limitations of traditional vaccine designs, Calder aims to deliver solutions that provide better safety, durability, and effectiveness for at-risk populations. Ultimately, their goal is to prevent severe illnesses and reduce the healthcare burden, contributing to healthier lives for billions of people.

BryoSphere

Seed Round in 2023
BryoSphere is a company specializing in the manufacturing of specialty chemicals, employing moss plants and biotechnology methods in the production of their goods. The company is currently focused on the development of two key products: one for addressing skin hyperpigmentation in topical treatments, and another as an anti-cancer drug.

Xias Bio

Seed Round in 2023
Xias Bio is a biotechnology startup focused on producing recombinant proteins that enhance the delivery of functional ingredients for various sectors, including research, beauty, and healthcare. The company specializes in developing non-immunogenic natural motifs, which provide a superior platform for creating soluble and active ingredients with desirable properties such as improved gel and film formation and antioxidant effects. By offering an adaptable, animal product-free biomaterial, Xias Bio delivers tailored biological functionalities that outperform traditional synthetic and animal-based products. This innovation enables pharmaceutical and cosmetic companies to access non-toxic, non-immunogenic alternatives for a wide range of applications.

Veloz Bio

Seed Round in 2023
Veloz Bio is a biotechnology company established in 2021 and located in Monterrey, Nuevo León. The company specializes in molecular farming to develop and manufacture sustainable and affordable animal-free and alternative proteins. By leveraging efficient plant metabolism, Veloz Bio has created a rapid protein production system that enables scalable growth of new proteins. This innovation allows biotech firms to gain expertise in essential areas of protein production, including supercritical fluid extraction and membrane purification. Through its focus on alternative proteins, Veloz Bio aims to contribute to a more sustainable food supply.

QuantumCyte

Series A in 2023
QuantumCyte, Inc. is a technology platform company based in Sunnyvale, California, that specializes in cell analysis systems aimed at predicting drug efficacy and improving cancer treatment outcomes. Founded in 2014, QuantumCyte develops automated microdissection solutions for molecular pathology, utilizing digital tissue maps to isolate regions of interest that contain important biomarkers. By harnessing artificial intelligence in digital pathology, the company enables healthcare providers to perform precise single-cell analysis, enhancing the understanding of immune system and cancer biology.

Cell BioEngines

Pre Seed Round in 2023
Cell BioEngines, Inc. is a clinical-stage biotechnology company dedicated to the development of allogeneic "off-the-shelf" stem cell therapies for the treatment of various human diseases, with a particular focus on oncology. The company has created a blood stem cell-derived epigenetic platform designed to address challenges related to donor source availability, cellular potency, and the complexities of manufacturing clinical-grade cell products. By leveraging this innovative platform, Cell BioEngines aims to produce cell-based therapies that can provide long-lasting benefits to patients, ultimately striving to transform cancer into a curable disease.

CroBio

Convertible Note in 2023
CroBio Ltd is an agricultural biotechnology company based in Macclesfield, United Kingdom, founded in 2019 by experts in microbiology and engineering. The company focuses on developing environmentally sustainable solutions to combat global agricultural drought. Its technology leverages genetically engineered root-associated bacteria that produce a sponge-like biomaterial, facilitating biologically active water retention in soil. This innovative approach aims to improve soil health and enhance water management in agricultural practices.

Avisa Myko

Seed Round in 2023
Avisa Myko Inc. is a biotechnology company based in San Francisco, California, specializing in the production of natural, water-soluble melanin. The company has developed a patented technology that allows for the large-scale and cost-effective manufacturing of melanin, which is used across various industries, including cosmetics, biomedicine, and environmental applications. Avisa Myko's melanin offers protection against ionizing radiation and is integrated into products such as latex, fabrics, laminated plastics, and glass. Additionally, the company is working on formulating a sunscreen that utilizes melanin as a natural ultraviolet blocker, eliminating the need for traditional chemical or mineral UV filters. By focusing on sustainable solutions, Avisa Myko aims to enhance human health and environmental safety through its innovative melanin products.

Bloomlabs

Seed Round in 2023
Bloomlabs provides a method to catalyze waste value by regenerating it as adaptable and appealing bio-plastics and textile fibers. It envisions a future in which outmoded, resource-intensive processes are phased out in favor of cutting-edge, sustainable, and scalable alternatives.

TippingPoint Biosciences

Seed Round in 2023
TippingPoint Biosciences is focused on developing therapeutics that address diseases linked to defects in DNA packaging, including various cancers and neurodegenerative disorders. Utilizing a drug discovery platform, the company aims to identify innovative treatments that specifically target unique genome packaging states associated with these diseases. This approach not only facilitates the treatment of cancers but also supports the development of stem cell therapies by addressing the underlying issues of dysfunctional genome packaging. Through its efforts, TippingPoint Biosciences seeks to advance medical care and improve patient outcomes in complex genetic conditions.

California Cultured

Convertible Note in 2023
California Cultured is a food company based in Davis, California, that specializes in producing sustainable, lab-grown cocoa through advanced cellular agriculture techniques. Founded in 2020, the company aims to create cocoa that is less bitter and requires less sugar, enhancing the taste while promoting health benefits. By stimulating cocoa cells with common food ingredients, California Cultured ensures the growth of premium-quality cocoa without the ethical and environmental issues associated with traditional cocoa production, such as slavery and deforestation. This innovative approach allows customers to enjoy delicious cocoa products that are both sustainable and socially responsible.

Via BioFuels

Pre Seed Round in 2023
VIA BioFuels is a biotechnology research company based in Houston, Texas, founded in 2023. The company focuses on developing proprietary engineered yeast strains, specifically S. cerevisiae, to produce energy-dense drop-in fuels, particularly aromatic 3-methyl anisole (3-MA), from conventional ethanol feedstocks. VIA BioFuels' technology is designed to be scalable, leveraging existing ethanol production technologies and infrastructure. By producing high-purity synthetic aromatic substances, the company enhances the market potential of 3-MA, allowing it to be transformed into other valuable compounds. This innovation enables consumers to transition to alternative fuels without the constraints of blending restrictions, positioning VIA BioFuels as a significant player in the renewable energy sector.

Pannex Therapeutics

Seed Round in 2023
Pannex Therapeutics is a New York-based biopharmaceutical startup focused on developing innovative cancer therapies through the use of Pannexin 1 channel (Panx1) blockers. This new class of drugs aims to inhibit multiple pathways essential for the growth, spread, and survival of cancer cells. The company's research emphasizes high specificity for cancer cells, aiming to enhance treatment effectiveness while ensuring safety. By targeting these pathways, Pannex Therapeutics seeks to transform cancer therapy and provide options that minimize side effects and reduce the risk of addiction, particularly in the context of chronic pain management.

Diadem Biotherapeutics

Convertible Note in 2023
Diadem Biotherapeutics is a biotechnology company dedicated to developing bio-therapeutical materials through organic methods. The company specializes in the creation of exosomes, which are cell-free vesicles that can be genetically engineered, manufactured, and purified. Diadem's innovative platform focuses on signaling through validated targets, offering potential treatments for various chronic inflammatory and autoimmune conditions, as well as cancers. By leveraging these technologies, Diadem aims to provide clinicians with effective solutions for managing immunopathologies.

AlkaLi Labs

Seed Round in 2023
AlkaLi Labs is a biotechnology research company based in San Francisco, California, established in 2023. The company focuses on developing biological solutions to harness domestic mineral resources. Currently operating in stealth mode, AlkaLi Labs aims to innovate in the field of biotechnology, leveraging biological processes to unlock valuable minerals.

Kresko RNAtech

Seed Round in 2023
Kresko RNAtech is a biotechnology company focused on the development and production of nutraceuticals. The company specializes in identifying bioactive ribonucleic acid (RNA) from natural sources, utilizing advanced techniques such as machine learning and bioinformatics. By uncovering RNAs that may offer health benefits, Kresko RNAtech aims to enhance human well-being and help individuals manage stressful and changing conditions through innovative RNA technologies.

Gozen Bioworks

Seed Round in 2023
Gozen Bioworks offers solutions and biomaterials developed with a biomimicry approach by combining science, art, philosophy, and design to raise awareness and provide help to the planet, living creatures, and humanity. They develop and invent high-performance microbe-derived materials from natural inputs, such as next-generation leather, biotextiles, bioplastics, packaging, and interior materials.

Geltor

Convertible Note in 2023
Geltor, Inc. is a biodesign company based in San Leandro, California, that specializes in producing bioactive, animal-free collagens and proteins for various applications in beauty, nutrition, and wellness. Established in 2015, Geltor offers innovative products such as Collume, which promotes skincare cellular regeneration and dermal synthesis, and HumaColl21, which enhances skin health by boosting collagen and elastin levels. Additionally, the company provides vegan collagen peptides and other novel proteins designed for functional food and nutraceutical formulations. Geltor's products are sustainably cultivated and clinically validated, allowing businesses to create effective, plant-based solutions that contribute to a more sustainable future.

Forte Protein

Convertible Note in 2023
Forte Protein is a biotechnology company founded in 2021 and headquartered in Trumansburg, New York. The company focuses on developing an expression system to produce bio-identical animal proteins, aiming to provide a sustainable alternative to traditional animal agriculture. By offering a complete spectrum of plant-based proteins that mimic the characteristics of animal proteins, Forte Protein seeks to eliminate the carbon footprint associated with animal farming, thus catering to consumers looking for environmentally friendly protein options.

Unibaio

Pre Seed Round in 2023
Unibaio specializes in biodegradable nano-encapsulation technology aimed at optimizing agrochemical delivery while minimizing environmental impact. The company develops innovative materials that create micro-nanocapsules, which enhance the efficacy of fertilizers and pesticides by improving their uptake and reducing harmful chemical runoff. Unibaio's solutions enable pesticide manufacturers to adjust their formulations to comply with stringent environmental regulations without altering the active ingredients used by farmers. By using natural compounds such as shrimp waste and clay, Unibaio promotes a circular economy, contributing to lower application costs for farmers and improved agricultural yields. Their technology is applicable across various pesticide and fertilizer types, including traditional chemicals and organic options, ultimately supporting the agricultural sector in reducing toxicity and enhancing the health of crops.

Stämm Biotech

Series B in 2023
Stämm Biotech is a San Francisco-based company specializing in advanced bioproduction systems designed to address the scaling challenges in the biotech industry. Founded in 2014, Stämm has developed an innovative biomanufacturing solution that integrates microfluidics, electroporation, and robotics, resulting in a compact, all-in-one Bioprocessor. This system has demonstrated productivity levels at least 70 times greater than traditional bioreactors, enabling clients to miniaturize bioreactors and optimize conditions more efficiently. Stämm's technology incorporates various sensors to monitor biological, physical, and chemical variations throughout the bioprocess, facilitating a streamlined approach to microbial growth and monoclonal cell line development. By transforming large-scale biotech operations into a more manageable micro-factory network, Stämm aims to unlock significant market potential in the coming years.

Beeflow

Convertible Note in 2023
Beeflow S.A., founded in 2016 and based in Buenos Aires, Argentina, specializes in providing professional pollination services to farmers. The company leverages scientific knowledge and technology to enhance bee populations, developing organic compounds that improve the immune systems of bees and guide them to pollinate specific crops. This approach not only helps increase crop yields—reported to be between 20-90% for various fruits such as blueberries, almonds, raspberries, and kiwifruit—but also addresses the decline in bee populations. By focusing on the health and efficiency of bees, Beeflow aims to maintain the security of plant ecosystems and support sustainable agriculture practices.

Cayuga Biotech

Seed Round in 2023
Cayuga Biotech is a startup focused on developing innovative hemostatic drugs and devices aimed at reducing uncontrollable bleeding, a leading cause of death from traumatic injuries. The company utilizes a polyphosphate-based drug that enhances the body's natural clotting ability, effectively promoting clot formation at injury sites while minimizing potential side effects. Cayuga's product pipeline includes a clinic-ready drug for life-threatening bleeding and therapeutics in the discovery stage for rare inherited bleeding disorders, central nervous system bleeding, severe burns, and non-healing wounds. By harnessing the body's innate coagulation response, Cayuga Biotech aims to improve survival rates and reduce disability associated with trauma.

Particella

Convertible Note in 2023
Particella specializes in the development of innovative lipid nanoparticle technology designed for the oral delivery of mRNA and other nucleic acids. This proprietary approach aims to transform the way biological medicines are administered by utilizing the intestinal tract to secrete proteins into the bloodstream, effectively allowing for the conversion of protein biologics into oral drugs. The company’s technology seeks to address existing limitations in the delivery of biological medicines, presenting potential advancements in preventing gastrointestinal diseases in patients.

DNALite Therapeutics

Convertible Note in 2023
DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Mimio

Seed Round in 2023
Mimio Health is a nutraceutical company dedicated to the research and production of mimetic supplements. Its innovative fasting mimetic formulation is based on clinical research and utilizes a carefully selected combination of bioactive human metabolites. This formulation aims to replicate the body’s natural response to fasting, offering the potential health benefits of fasting without the need to undergo the fasting process. Mimio's products focus on promoting cellular health, providing anti-inflammatory and antioxidant effects that may help combat age-related chronic inflammation and cellular damage.

FluoSphera

Pre Seed Round in 2023
FluoSphera is a company focused on the development of innovative drugs that minimize adverse side effects and reduce reliance on animal testing. By addressing the complexities of human physiological responses, FluoSphera aims to assist organizations in creating safer pharmaceuticals and protecting populations from harmful compounds. Their approach emphasizes efficiency in drug discovery, ultimately enhancing public health and safety.

CroBio

Seed Round in 2023
CroBio Ltd is an agricultural biotechnology company based in Macclesfield, United Kingdom, founded in 2019 by experts in microbiology and engineering. The company focuses on developing environmentally sustainable solutions to combat global agricultural drought. Its technology leverages genetically engineered root-associated bacteria that produce a sponge-like biomaterial, facilitating biologically active water retention in soil. This innovative approach aims to improve soil health and enhance water management in agricultural practices.

Bioeutectics

Seed Round in 2023
Bioeutectics focuses on creating environmentally friendly industrial products by providing high-performance, natural solvents. Utilizing proprietary eutectic technology, the company produces solvents that mimic the natural processes of plants, using 100% renewable resources. This innovation allows Bioeutectics to replace traditional petrochemical solvents in various industrial applications, promoting sustainability. Their product line caters to diverse sectors, including food, pharmaceuticals, and personal care, and is designed to be non-toxic, biodegradable, and customizable to meet specific industry needs. Through these advancements, Bioeutectics aims to lead the market in offering sustainable alternatives that enhance environmental responsibility in industrial processes.

BiomeSense

Seed Round in 2023
BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Lillianah Technologies

Seed Round in 2023
Lillianah is a team of scientists dedicated to addressing environmental challenges through innovative carbon capture technology. Their focus is on optimizing the biological pump in oceans to restore balance to marine ecosystems adversely affected by pollution, fertilizer runoff, and various external factors. By harnessing the potential of oceans, Lillianah aims to reverse the negative impacts on the environment, contributing to a healthier planet.

Veloz Bio

Seed Round in 2023
Veloz Bio is a biotechnology company established in 2021 and located in Monterrey, Nuevo León. The company specializes in molecular farming to develop and manufacture sustainable and affordable animal-free and alternative proteins. By leveraging efficient plant metabolism, Veloz Bio has created a rapid protein production system that enables scalable growth of new proteins. This innovation allows biotech firms to gain expertise in essential areas of protein production, including supercritical fluid extraction and membrane purification. Through its focus on alternative proteins, Veloz Bio aims to contribute to a more sustainable food supply.

Multus

Series A in 2023
Multus is a London-based company established in 2019 that specializes in providing affordable and efficient growth media for the cultivated meat industry. By employing a machine learning approach, Multus develops entirely animal-free growth media tailored specifically for animal cells, helping cultivated meat companies scale their production while maintaining high performance. The company focuses on optimizing growth factor proteins produced by genetically engineered microorganisms, thereby eliminating the environmental drawbacks associated with traditional animal serum-based media. This innovative solution supports the growth of diverse animal cell types and tissues, enabling clients to produce sustainable meat products while minimizing the environmental and economic impacts of conventional meat production.

Atlantic Fish Company

Pre Seed Round in 2023
Atlantic Fish Company is focused on producing cultivated seafood through cellular agriculture, operating from its headquarters in Raleigh-Durham, North Carolina. The company aims to provide sustainable seafood options by cultivating fish in a controlled environment. This innovative approach allows Atlantic Fish Company to offer fresh fish meat that maintains the natural taste while minimizing the environmental impact associated with traditional fishing practices. By leveraging cellular agriculture, the company seeks to meet the growing demand for sustainable protein sources.

Michroma

Seed Round in 2023
Michroma Corporation is a biotechnology company that specializes in producing natural thermostable colorants derived from filamentous fungi through a fermentation process. Founded in 2019 and based in both San Francisco, California, and Rosario, Argentina, Michroma aims to replace synthetic pigments and those sourced from animals and plants with sustainable, naturally produced alternatives. The company harnesses synthetic biology to develop proprietary fungal strains that generate high-performance ingredients in bioreactors. Currently, Michroma is prototyping its innovative pH-stable and heat-stable food colorants in collaboration with leading food and beverage and cosmetic companies. Additionally, the company is exploring the production of mycoprotein and other ingredients, making strides in the sustainable ingredients market.

Cybele Microbiome

Convertible Note in 2022
Cybele Microbiome is a company focused on enhancing skin health through precision control of the microbiome. Utilizing a proprietary AI platform that integrates machine learning with advanced biotechnology, Cybele Microbiome develops customized skincare products aimed at improving the skin's natural barrier. The company's approach includes genetic sequencing methods and the use of sustainable nutrient sources to create targeted natural solutions that support the microbiome. By leveraging AI tools and microbiome science, Cybele Microbiome seeks to revolutionize skincare, enabling customers to maintain skin integrity while promoting overall health and longevity.

Prolific Machines

Convertible Note in 2022
Prolific Machines is a biotechnology company based in San Francisco, California, founded in 2020. It specializes in developing advanced cell technologies aimed at transforming the production of cells for sustainable applications, particularly in the cultivated meat industry. The company focuses on high-scale precision cell-differentiation techniques that enhance the efficiency, quality, reproducibility, and sustainability of cell production. Additionally, Prolific Machines is engaged in research and development efforts related to clean meat and cell therapies, utilizing innovative approaches to create better sustainable options. Through its work, the company aims to promote a healthier future for both humanity and the planet.

Aja Labs

Seed Round in 2022
Aja Labs is a biotechnology company founded in 2019 and based in San Francisco, California. The company specializes in producing biodegradable fiber designed to replace plastic-based fibers. By utilizing plant materials, Aja Labs creates fiber that mimics the appearance and texture of human hair, providing a sustainable alternative to chemical-laden synthetic fibers and human hair in the production of hair extensions. Aja Labs aims to offer innovative solutions that cater to diverse communities while promoting environmental sustainability.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.